Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 4/20 | 0.36 |
| ▸ | CTSL | P07711 | 3/20 | 0.36 |
| ▸ | CTSB | P07858 | 3/20 | 0.36 |
| ▸ | CTSD | P07339 | 1/20 | 0.36 |
| ▸ | CTSH | P09668 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 6/20 | 0.35 |
| ▸ | F11 | P03951 | 1/20 | 0.30 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2028799 | 1.00 | CTSS (0.36) | CTSSCTSLCTSBCTSDCTSH | |
| SCHEMBL10069060 | 0.85 | CTSS (0.44) | CTSSCTSLCTSBCTSDCTSH | |
| SCHEMBL2024647 | 0.83 | CTSL (0.34) | CTSSCTSLCTSBCTSHCTSK | |
| SCHEMBL3343422 | 0.83 | CTSL (0.34) | CTSSCTSLCTSBCTSHCTSK | |
| SCHEMBL1567247 | 0.83 | CTSL (0.34) | CTSSCTSLCTSBCTSHCTSK | |
| SCHEMBL13908244 | 0.81 | CTSS (0.32) | CTSSCTSLCTSBCTSDCTSH | |
| SCHEMBL3097223 | 0.81 | CTSS (0.32) | CTSSCTSLCTSBCTSDCTSH | |
| SCHEMBL13908260 | 0.81 | CTSS (0.32) | CTSSCTSLCTSBCTSDCTSH | |
| SCHEMBL7998425 | 0.80 | PSEN1 (0.32) | CTSSCTSLCTSBCTSD | |
| SCHEMBL8004071 | 0.80 | PSEN1 (0.32) | CTSSCTSLCTSBCTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110160300-A1 | Renin Inhibitors and Methods of Use Thereof | VITAE PHARMACEUTICALS, INC. | 2011-06-30 | — | — | US | disclosed |
| US-20100160424-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. | 2010-06-24 | — | — | US | disclosed |
| WO-2009154766-A1 | RENIN INHIBITORS AND METHOD OF USE THEREOF | VITAE PHARMACEUTICALS, INC. (US) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160424-A1 | RENIN INHIBITORS | ACE, REN, DNPEP | CTSS 56/4885CTSL 61/4885CTSB 54/4885 |
| US-20110160300-A1 | Renin Inhibitors and Methods of Use Thereof | REN, ACE, AGTR1 | CTSS 54/4885CTSL 47/4885CTSB 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.